Jazz Pharmaceuticals, Inc. vs Johnson & Johnson
JAZZ vs JNJ — side-by-side comparison from reported financials. JAZZ leads 4, JNJ leads 6 of 10 comparable metrics.
Jazz Pharmaceuticals, Inc.
JAZZ · Healthcare
$218.42-1.81%Mixed
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | JAZZ | JNJ |
|---|---|---|
| Price | $218.42 | $261.79 |
| Market cap | $14.2B | $631B |
| Revenue (TTM) | $4.60B | $97.9B |
| Revenue growth | +5.3% | +5.6% |
| Net margin | 20.4% | 21.5% |
| Free cash flow | $1.59B | $22.2B |
| Net cash (debt) | ($2.94B) | ($27.8B) |
| 1-year price return | +58.1% | +37.0% |
| P/E | 15.1 | 29.9 |
| P/E vs own history (cheap-side %) | 90% | 16% |
| Dividend yield | — | 2.00% |
| Return on equity | 21% | 26% |
| Altman Z-score | 2.13 | — |
| CV checks passed | 9 of 10 | 10 of 10 |
| Employees | 2,890 | 140,800 |
Full résumé-style profiles: JAZZ CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.